アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/2570/2019, ivr-215) ; a/cambodia/e0826360/2020 (h3n2)-like strain (a/cambodia/e0826360/2020, ivr-224); b/washington/02/2019-like strain (b/washington/02/2019, wild type) - suspension for injection in pre-filled syringe - 0.5 microgram(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

surface antigen, inactivated - influenza virus surface antigens - suspension for injection

欧州連合 - 英語 - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - influenza, human - vaccines - prophylaxis of influenza in the elderly (65 years of age and older).fluad tetra should be used in accordance with official recommendations.

欧州連合 - 英語 - EMA (European Medicines Agency)

seqirus s.r.l.  - influenza virus surface antigens, inactivated: a/viet nam/1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; potassium chloride - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. the vaccine is indicated for use in adults and children 6 months of age and older. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

欧州連合 - 英語 - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza caused by a (h1n1v) 2009 virus.focetria should be used in accordance with official guidance.

欧州連合 - 英語 - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,

欧州連合 - 英語 - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

seqirus s.r.l. - a/guangdong-maonan/swl 1536/2019 (h1n1)pdm09-like strain (a/guangdong-maonan/swl 1536/2019, cnic-1909); a/hong kong/2671/2019 (h3n2)-like strain (a/hong kong/2671/2019, ivr-208); b/washington/02/2019-like strain (b/washington/02/2019, wild type) - suspension for injection in pre-filled syringe - . - influenza vaccines; influenza, inactivated, split virus or surface antigen - influenza vaccine - prophylaxis of influenza, especially in those who run an increased risk of associated complications

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

seqirus s.r.l. - a/michigan/45/2015 (h1n1) pdm09 - like strain (a/singapore/gp1908/2015, ivr-180a); a/singapore/imfimh-16-0019/2016 (h3n2)-like strain (a/singapore/infimh-16-0019/2016,nib-104); b/colorado/06/2017-like strain (b/victoria/2/87 lineage)(b/maryland/15/2016,nymc bx-69a) - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen - influenza vaccine - active immunisation against influenza in the elderly (65 years of age and over. refer to spc for detailed information.